ArticleJournal of psychiatric research2025
Clinical heterogeneity in major depressive disorder underlies comorbidity with functional disorders.
Article in Journal of psychiatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Clinical AI-Based System (MoodMon) for Affective Disorders: Algorithm Development and Validation.JMIR AI · 2026Article
- From Xenobiotic Exposure to Neuroinflammation: Mechanisms Linking Lipopolysaccharide Signaling to Depressive-like Behavior.Journal of xenobiotics · 2026Review
- Symptom-specific genetics reveal heterogeneity within major depressive disorder.medRxiv : the preprint server for health sciences · 2026Article
- Disentangling comorbidity: symptom dimensions of internalizing and functional disorders in a large general population sample.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The comorbidities between MDD and functional disorders (FDs), such as fibromyalgia (FM), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and irritable bowel syndrome (IBS) remain largely unexplored. We analyzed data from 10,563 lifetime MDD cases (mean age = 50.5 (SD = 11.9), 71.8% female) from the Lifelines Cohort Study. Lifetime MDD symptoms from DSM-5 criterion A were assessed in 2018. Current FDs were assessed according to diagnostic criteria between 2014 and 2017. First, we modeled the effect of 12 disaggregated MDD symptoms on FM, ME/CFS, and IBS diagnoses using multiple logistic regression. Most, but not all, MDD symptoms were associated with FD diagnoses, suggesting that some features of MDD are particularly important to the comorbidity between MDD and FDs. Next, we used Latent Class Analysis to classify MDD cases based on their symptoms to explore whether MDD - FD comorbidities were associated with specific symptom profiles. We found that a five-class solution provided the best balance of model fit and entropy. Two classes, termed severe typical and anhedonia/weight gain, associated with increased prevalence of all FDs. The severe typical class was equally associated with FM and ME/CFS, while the anhedonia/weight gain class was differentially associated with pairs of FDs suggesting that features of the anhedonia/weight gain class are uniquely related to different FDs with varying magnitudes of effect and, possibly, different mechanisms. The comorbidity between MDD and FDs does not appear to result from a single mechanism. Identification of the mechanisms that underlie the association between MDD and FDs is a priority for future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.